Welcome to our dedicated page for Waters SEC filings (Ticker: WAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Waters Corporation’s disclosures can feel like running an entire chromatography sequence just to isolate one data point. With complex discussions of consumable margins, mass-spectrometry R&D, and global manufacturing risk, investors often struggle to locate what matters inside a 10-K or 10-Q.
Stock Titan addresses that problem head-on. Our AI-powered summaries turn Waters SEC filings explained simply into reality: algorithms flag segment revenue shifts, translate technical terms, and push Waters Form 4 insider transactions real-time to your dashboard. Whether you are comparing capital expenditures or tracking Waters executive stock transactions Form 4, you receive context instead of raw jargon.
Here’s where you’ll find fast answers to the questions investors actually ask:
- 10-K Annual Report � get the Waters annual report 10-K simplified with AI call-outs on chromatography consumable growth and service contract backlog.
- 10-Q Quarterly Earnings � our AI spots trends in every Waters quarterly earnings report 10-Q filing and delivers clear Waters earnings report filing analysis.
- 8-K Material Events � receive instant alerts with Waters 8-K material events explained so you never miss product-launch news or executive changes.
- Form 4 � monitor Waters insider trading Form 4 transactions and gauge sentiment before key announcements.
- DEF 14A Proxy Statement � uncover Waters proxy statement executive compensation details without scrolling through appendices.
From understanding Waters SEC documents with AI to drilling into consumable profitability, Stock Titan delivers comprehensive coverage and real-time insight—so you spend less time decoding disclosures and more time making decisions.
Waters Corp. (WAT) Q2 2025 10-Q highlights
- Net sales: $771.3 m, up 8.9 % YoY; YTD $1.43 bn, +6.5 %.
- Mix: Product $473.4 m (+8.8 %), Service $297.9 m (+9.0 %).
- Profitability: Q2 operating income $188.2 m (24.4 % margin vs 26.7 %), essentially flat YoY. Net income $147.1 m (+3 %); diluted EPS $2.47 (vs $2.40). YTD EPS $4.50 (+9.2 %).
- Cash & debt: Cash $367 m (�$42 m YTD); total debt $1.46 bn (�$169 m). Current $260 m of notes re-classified as short-term; amended credit facility now $1.8 bn maturing 2030.
- Working capital: Inventories $541 m (+13 % since FY-end); A/R flat; deferred revenue up $113 m to $420 m.
- Cash flow: Operating cash flow $300.7 m (-5 % YoY); capex & software $48 m; free cash flow ~$253 m. Share buybacks limited to $14 m for RSU tax withholding.
- Acquisitions & strategy: Closed May 2025 purchase of Halo Labs for $35 m (adds particle-analysis tech). Subsequent event: definitive agreement (13 Jul 25) to acquire BD Biosciences & Diagnostic Solutions for ~$17.5 bn cash/stock—transformative if completed.
- Guidance: none provided; management notes FX headwinds, ERP roll-out ($130 m over 3 yrs) and higher tax rate (17.2 % vs 15.7 %).
- Balance-sheet strength: Equity $2.16 bn vs $1.83 bn FY-end; leverage (net debt/EBITDA) falls to ~2.7Ă— pre-BD deal.
Overall, Waters delivered mid-single-digit growth and steady EPS, while preparing for a large, leverage-adding acquisition that could significantly reshape its scale and risk profile.
Waters Corporation (NYSE: WAT) filed a Form 8-K on 4 Aug 2025. Under Item 2.02 the company states it has released its operating results for the quarter ended 28 Jun 2025; the detailed numbers are contained only in the furnished press release (Exhibit 99.1) and are not included in the filing itself.
The 8-K also contains extensive “Additional Information� language regarding a proposed transaction involving Waters, Augusta SpinCo Corporation and Becton, Dickinson and Company (BD). The parties intend to file a registration statement on Form S-4 (Waters) and Form 10 (SpinCo) with the SEC. Investors are urged to read the future proxy/information statements when available. No terms, consideration, timing or strategic rationale for the deal are disclosed in this document.
Other sections are routine: confirmation of securities registration, exhibit index (press release and XBRL cover), and signature by CFO Amol Chaubal. The information in Item 2.02 is furnished, not filed, and therefore is not subject to Exchange Act Section 18 liability nor automatically incorporated by reference in other filings.
Form 144 filing for Kiniksa Pharmaceuticals International, plc (KNSA) discloses a proposed sale of 18,900 Class A ordinary shares on or after 14 July 2025. The broker named is Charles Schwab & Co. and the estimated aggregate market value is $542,860, implying a reference price of roughly $28.7 per share. Kiniksa has 42.34 million shares outstanding, so the planned trade represents about 0.05 % of total shares.
The filing also lists six insider sales over the last three months by Eben Tessari totaling 112,167 shares for $3.21 million in gross proceeds. If the new sale is executed, cumulative insider disposals would reach 131,067 shares (� 0.31 % of shares outstanding) and � $3.75 million in proceeds.
No information is provided on 10b5-1 plan adoption dates, but the signer affirms no undisclosed material adverse information. There are no earnings figures, business updates, or transaction proceeds earmarked for corporate purposes; the filing serves solely as a notice of potential insider liquidity.
Waters Corporation (NYSE: WAT) filed an 8-K to disclose a material strategic transaction. The company has signed an agreement to combine Becton, Dickinson & Company’s (BD) Biosciences and Diagnostics Solutions business with Waters (the “Proposed Transaction�). No financial terms, deal value, or pro-forma forecasts were provided in the filing.
Key highlights
- Transaction scope: The combination would add BD’s Biosciences and Diagnostics Solutions unit to Waters� existing analytical-instrument franchise, potentially expanding Waters� end-market exposure from life-science research into clinical diagnostics.
- Communication timeline: A joint conference call and webcast was scheduled for 8:00 a.m. ET on 14 July 2025. The related press release (Ex. 99.1) and investor presentation (Ex. 99.2) are furnished—but not filed—under Regulation FD.
- Regulatory & shareholder approvals: Completion is subject to customary closing conditions, including Waters shareholder approval and multiple regulatory clearances.
- Forward-looking statements & risks: Waters lists 17 specific risk factors that could cause the deal to fail or the combined company to under-perform. Prominent risks include antitrust hurdles, integration complexity, cost overruns, talent retention, tax treatment, and potential litigation.
Accounting treatment: Because the information is furnished under Item 7.01 (Regulation FD) rather than 1.01 (Entry into a Material Definitive Agreement), it is not deemed “filed� for Section 18 liability.
Take-away: The announcement signals Waters� intent to accelerate growth through a transformative acquisition, but material uncertainties remain until financial terms, financing structure, and regulatory feedback are disclosed.
Waters Corp. (NYSE: WAT) has filed a Form 4 indicating that director Wei Jiang acquired 68.35 common-stock units on 30 June 2025. The units were issued at a stated price of $0.00 because they represent deferred, stock-settled compensation in lieu of cash director fees under the company’s 1996 Non-Employee Director Deferred Compensation Plan. Each unit converts into one share of common stock on 1 January 2035, in line with the reporting person’s prior deferral election. Following the issuance, Jiang’s direct beneficial ownership rises to 2,478.57 shares. No derivative securities were bought or sold, and no shares were disposed of. The filing reflects a routine, low-dollar insider acquisition that marginally increases director equity alignment but is not material to Waters� overall share count or valuation.
Waters Corp (WAT) filed a Form 4 on 26 June 2025 for insider Robert L. Carpio III, Senior Vice President of the Waters Division. On 24 June 2025, the company withheld 134 shares of common stock (transaction code F) at $346.80 per share to cover tax obligations associated with the vesting of previously granted restricted stock units. The withholding represents an estimated tax value of roughly $46.5 thousand. Following the transaction, Carpio directly owns 2,656 shares of WAT. No open-market trading or derivative activity was reported, indicating the event is administrative rather than strategic.
FAQ
What is the current stock price of Waters (WAT)?
What is the market cap of Waters (WAT)?
What is Waters Corporation known for?
Which industries does Waters Corporation serve?
How does Waters generate revenue?
What are the key product categories offered by Waters?
What distinguishes Waters� technology from its competitors?
How global is Waters' operational footprint?
How does Waters address the challenges of modern analytical demands?
What strategies help maintain Waters� market position?
